Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome.
Barettino A, González-Gómez C, Gonzalo P, Andrés-Manzano MJ, Guerrero CR, Espinosa FM, Carmona RM, Blanco Y, Dorado B, Torroja C, Sánchez-Cabo F, Quintas A, Benguría A, Dopazo A, García R, Benedicto I, Andrés V. Barettino A, et al. Among authors: blanco y. J Clin Invest. 2024 Oct 1;134(22):e173448. doi: 10.1172/JCI173448. J Clin Invest. 2024. PMID: 39352768 Free PMC article.
Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson-Gilford progeria syndrome.
Macías Á, Díaz-Larrosa JJ, Blanco Y, Fanjul V, González-Gómez C, Gonzalo P, Andrés-Manzano MJ, da Rocha AM, Ponce-Balbuena D, Allan A, Filgueiras-Rama D, Jalife J, Andrés V. Macías Á, et al. Among authors: blanco y. Cardiovasc Res. 2022 Jan 29;118(2):503-516. doi: 10.1093/cvr/cvab055. Cardiovasc Res. 2022. PMID: 33624748 Free PMC article.
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
Levitz D, Chao Foong Y, Sanfilippo P, Spelman T, Rath L, Roldan A, Lal A, Monif M, Jokubaitis V, Ozakbas S, Alroughani R, Boz C, Terzi M, Kalincik T, Blanco Y, Foschi M, Surcinelli A, Buzzard K, Skibina O, Laureys G, Van Hijfte L, Ramo-Tello C, Soysal A, Sanchez-Menoyo JL, Habek M, Cartechini E, Rojas JI, Karabudak R, Willekens B, Al-Harbi T, Fragoso Y, Castillo-Triviño T, Decoo D, Aragon de Vecino MC, Skromne E, Sirbu CA, Zhu C, Merlo D, Gresle M, Butzkueven H, Van Der Walt A. Levitz D, et al. Among authors: blanco y. Ther Adv Neurol Disord. 2024 Nov 7;17:17562864241278496. doi: 10.1177/17562864241278496. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39525878 Free PMC article.
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis.
Villoslada P, Solana E, Alba-Arbalat S, Martinez-Heras E, Vivo F, Lopez-Soley E, Calvi A, Camos-Carreras A, Dotti-Boada M, Bailac RA, Martinez-Lapiscina EH, Blanco Y, Llufriu S, Sanchez Dalmau BF. Villoslada P, et al. Among authors: blanco y. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200288. doi: 10.1212/NXI.0000000000200288. Epub 2024 Aug 30. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39213469 Free PMC article.
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, Guasp M, Naranjo L, Ruiz-García R, Caballero E, González-Álvarez V, Delgadillo V, Romeu G, Del-Prado-Sánchez C, Cabrera-Maqueda JM, Benito-León J, Iñiguez C, Garcia-Dominguez JM, Calles C, Cano A, Álvarez-Bravo G, González-Suárez I, Oreja-Guevara C, Ros M, Millan-Pascual J, Meca-Lallana JE, Borrega Canelo L, Martín-Martínez J, Palao M, Gracia J, Villaverde-González R, Llufriu S, Blanco Y, Saiz A, Dalmau J, Sepulveda M, Armangue T; Spanish MOGAD study group. Fonseca E, et al. Among authors: blanco y. Neurology. 2024 Sep 24;103(6):e209682. doi: 10.1212/WNL.0000000000209682. Epub 2024 Aug 27. Neurology. 2024. PMID: 39190859
CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year.
Cabrera-Maqueda JM, Sepulveda M, García RR, Muñoz-Sánchez G, Martínez-Cibrian N, Ortíz-Maldonado V, Lorca-Arce D, Guasp M, Llufriu S, Martinez-Hernandez E, Armangue T, Fonseca EG, Alba-Isasi MT, Delgado J, Dalmau J, Juan M, Saiz A, Blanco Y. Cabrera-Maqueda JM, et al. Among authors: blanco y. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200292. doi: 10.1212/NXI.0000000000200292. Epub 2024 Aug 6. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39106426 Free PMC article.
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: blanco y. Brain. 2024 Aug 5:awae260. doi: 10.1093/brain/awae260. Online ahead of print. Brain. 2024. PMID: 39101570
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T. Roos I, et al. Among authors: blanco y. Mult Scler. 2024 Aug;30(9):1163-1175. doi: 10.1177/13524585241267211. Epub 2024 Aug 1. Mult Scler. 2024. PMID: 39087208
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, Laureys G, Van Wijmeersch B, Popescu V, Dhaene T, Deschrijver D, Waegeman W, De Baets B, Stock M, Horakova D, Patti F, Izquierdo G, Eichau S, Girard M, Prat A, Lugaresi A, Grammond P, Kalincik T, Alroughani R, Grand'Maison F, Skibina O, Terzi M, Lechner-Scott J, Gerlach O, Khoury SJ, Cartechini E, Van Pesch V, Sà MJ, Weinstock-Guttman B, Blanco Y, Ampapa R, Spitaleri D, Solaro C, Maimone D, Soysal A, Iuliano G, Gouider R, Castillo-Triviño T, Sánchez-Menoyo JL, Laureys G, van der Walt A, Oh J, Aguera-Morales E, Altintas A, Al-Asmi A, de Gans K, Fragoso Y, Csepany T, Hodgkinson S, Deri N, Al-Harbi T, Taylor B, Gray O, Lalive P, Rozsa C, McGuigan C, Kermode A, Sempere AP, Mihaela S, Simo M, Hardy T, Decoo D, Hughes S, Grigoriadis N, Sas A, Vella N, Moreau Y, Peeters L. De Brouwer E, et al. Among authors: blanco y. PLOS Digit Health. 2024 Jul 25;3(7):e0000533. doi: 10.1371/journal.pdig.0000533. eCollection 2024 Jul. PLOS Digit Health. 2024. PMID: 39052668 Free PMC article.
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD, Hegen H, Villar LM, Rejdak K, Sao-Aviles A, Carbonell-Mirabent P, Sastre-Garriga J, Mongay-Ochoa N, Berek K, Martínez-Yélamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke JN, Rosenstein I, Alvarez-Lafuente R, Castillo-Trivino T, Otaegui D, Llufriu S, Blanco Y, Sánchez López AJ, Garcia Merino JA, Fissolo N, Gutierrez L, Villacieros-Álvarez J, Monreal E, Valls-Carbó A, Wiendl H, Montalban X, Comabella M. Lunemann JD, et al. Among authors: blanco y. Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200270. doi: 10.1212/NXI.0000000000200270. Epub 2024 Jun 21. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38912898 Free PMC article.
204 results